Liquid Biopsy Market:
WiseGuyReports.com adds “Global Liquid Biopsy Market: Analysis By Biomarkers, Cancer Type, By Product: Opportunities and Forecast (2017-2024)” reports to its database.
Liquid Biopsy is a non-invasive alternative to surgical biopsy procedure that helps in the analysis of the sample of the blood or DNA to diagnose the tumour cells and gather a lot of information about that particular tumour. It is a sample test that provides information about the cancer cells at an early stage. The treatment plan can be made accordingly for the patients to treat and cure the disease. This test can be done frequently and multiple samples of blood can also be taken without using invasive procedures on the patients.
The evolution of various sensitive detection technologies in the healthcare sector has enabled the development of liquid biopsy that includes the screening for the presence of diseases, therapy section, monitoring the treatment response, studying the drug resistance, and the detection of residual disease after the surgery. The probability of the recurrence of diseases like cancer after its treatment can also be tested with the help of liquid biopsy. The changing lifestyles and growing health awareness among the population are increasing the use of liquid biopsy method.
Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/4583427-global-liquid-biopsy-market-analysis-by-biomarkers-c
As per the global liquid biopsy market report, the market accounted for US$899.55 million in the year 2018. In recent years, the global liquid biopsy market has witnessed considerable growth. Rising focus on immunotherapy to cure cancer, adoption of new diagnostic tests and the high capita healthcare expenditure among the global population is fuelling the growth of the global liquid biopsy market. The rising awareness for the early detection of cancer and the rise in cancer patients is also contributing to the growth of the global market.
Multiple research platforms and the various technological advances in the field of liquid biopsy have enabled cheaper and faster diagnosis of various chronic diseases. The market segmentation of liquid biopsy has been done based on cancer type, circulating biomarker and the product type.
On the basis of the cancer types, the global liquid biopsy market has been segmented as:
On the basis of circulating biomarker, the global liquid biopsy market has been split into:
ct-DNA is the most widely used biomarker for the diagnosis of pre and posts cancerous stage.
And on the basis of product type, the global liquid biopsy market has been categorized as:
The recent scientific advancement in the understanding of tumour cells, cell-free DNA/RNA are some major factors that have led to the growth of the liquid biopsy market. Countries like France, Germany, India, US, Canada, Mexico, China, Italy, Japan, South Africa, Saudi Arabia, Argentina and Brazil are mentioned in the report for the growth in the market share for Liquid Biopsy for a period from 2017 to 2018 and the forecast period from 2019 to 2024. The continuous research and the development of the testing procedures by the private manufacturers, government organizations and the increasing clinical trials in the testing laboratories are propelling the momentum of the market for liquid biopsy.
BIOCEPT, a provider for liquid biopsy test for cancer, has launched its Target Selector pan-TRK for detecting TRK biomarkers in cancer. The TRK protein present in the biomarker is associated with aggressive cancer in tumours like lung cancer. This test can determine the sensitivity and presence of NTRK fusions in the body.
For further information on this report, visit – https://www.wiseguyreports.com/reports/4583427-global-liquid-biopsy-market-analysis-by-biomarkers-c
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)